956928-36-2

Upstream product

• 109183-71-3 N-(tert-butoxycarbonyl)-L-cyclohexylglycine 
• 96-41-3 Cyclopentanol 
• 914604-31-2 (S)-tert-butoxycarbonylamino-cyclohexyl-acetic acid cyclopentyl ester 

Downstream Products

• 1018811-89-6 cyclopentyl (2S)-cyclohexyl{[(4-{[(3-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}benzyl)amino]methyl}cyclohexyl)methyl]amino}acetate 
• 1018674-43-5 cyclopentyl (2S)-cyclohexyl[(4-{[(3-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}benzyl)amino]methyl}benzyl)amino]acetate 
• 1018674-33-3 cyclopentyl (2S)-cyclohexyl[(3-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}benzoyl)amino]acetate 
• 1018674-32-2 (2E)-3-(3-{[(1S)-1-cyclohexyl-2-(cyclopentyloxy)-2-oxoethyl]carbamoyl}phenyl)acrylic acid 
• 1018811-88-5 cyclopentyl (2S)-({[4-(aminomethyl)cyclohexyl]methyl}amino)(cyclohexyl)acetate 
• 1022928-02-4 C₃₀H₄₉N₅O₅ 
• 1023296-42-5 C₂₄H₃₄N₄O₄ 
• 1022929-30-1 C₃₂H₅₁N₃O₅ 
• 1018674-51-5 methyl (2E)-3-[4-(1-{[(1S)-1-cyclohexyl-2-(cyclopentyloxy)-2-oxoethyl]amino}ethyl)phenyl]acrylate 
• 1018674-47-9 tert-butyl 4-{[(1S)-1-cyclohexyl-2-(cyclopentyloxy)-2-oxoethyl]amino}piperidine-1-carboxylate 
• 1018811-87-4 cyclopentyl (2S)-{[(4-{[(tert-butoxycarbonyl)amino]methyl}cyclohexyl)methyl]amino}(cyclohexyl)acetate 
• 1018674-41-3 cyclopentyl (2S)-[(4-{[(tert-butoxycarbonyl)amino]methyl}benzyl)amino](cyclohexyl)acetate 
• 1018674-40-2 cyclopentyl (2S)-cyclohexyl[(3-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}benzyl)amino]acetate 
• 1018674-36-6 cyclopentyl (2S)-cyclohexyl{[3-(4-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}phenoxy)propyl]amino}acetate 

Relevant academic research and scientific papers

P38 MAP KINASE INHIBITORS

Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is -N= or -CH=; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5 - 13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH2)z-X1-L1 -Y-NH-CHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members; z, Y, L1, and X1 are as defined in the specification; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 is the side chain of a natural or non-natural alpha amino acid.

HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE

Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent -N= or -C=; B is

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.

THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE

Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is -(C=O), an optionally substituted divalent ph

p38 MAP KINASE INHIBITORS

Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: (I), wherein: G is -N= or -CH=; D is an optionally substituted divale